The trial is enrolling patients with certain types of cancer across three dose groups to determine the maximum tolerated dose, recommended phase 2 dose and safety profile.
Alaunos expects initial data readout from the phase 1/2 trial in the second half of 2022.
Shares of the company declined 4.7% in recent trading activity.
Price: 0.51, Change: -0.03, Percent Change: -4.70
|-- Earnings Flash (AQS) AEQUUS PHARMACEUTICALS Repor...|
|Insider Buy: Bitnile Holdings|
|Insider Buy: Macerich|
|Insider Sell: Velodyne Lidar|
|Insider Sell: Xometry|